|
CV Information
 PROFESOR DATO' DR. MAFAUZY B. MOHAMED
| |
|---|---|
|
Grant's Name,"Project's Title" (Research Period)(Role)[Sponsorship]
| |
| 1 | EXTERNAL AGENCY (INTERNATIONAL), ""GOITER & CONGENITAL HIPOTORODISM"" (01.01.1995 - 01.01.1970) (Principal) [ INTERNATIONAL ATOMIC ENERGY AUSTRIA (IAEA) ] - Source: eR&I |
| 2 | , "17. A RANDOMIZED MULTICOUNTRY MULTICENTERDOUBLE BLIND PARALELL PLACEBO CONTROLLED STUDY OF THE EFFECTS OF ATRASENTAN ON RENAL OUTCOMES IN SUBJECTS WITH TYPE 2 DIABETES AND NEPHROPATHY SONAR:STUDY OF DIABETIC NEPHROPATHY" (12.02.2014 - 13.01.2016) [ AbbVie Inc ] - Source: HCMSv3 |
| 3 | , "A 24 WEEK, RANDOMIZED, DOUBLE BLIND, ACTIVE-CONTROLLED, PARALLEL GROUP TRIAL TO ASSESS THE SUPERIORITY OF ORAL LINAGLIPTIN AND METFORMIN COMPARED TO LINAGLIPTIN MONOTHERAPY IN NEWLY DIAGNOSED TREATMENT NAIVE UNCONTROLLED DIABETES MELLITUS PATIENTS" (08.02.2012 - 09.07.2014) [ Boehringer Ingelheim Singapore Pte. Ltd. ] - Source: HCMSv3 |
| 4 | , "A PHASE 3, RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALEL-GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY OF TWO DIFFERENT REGIMENS OF MIPOMERSEN IN PATIENTS WITH FAMILIAL HYPERCHOLESTROLEMIA AND INADEQUATELY CONTROLLED LOW DENSITY LIPOPROTEIN CHOL" (23.12.2011 - 17.01.2013) [ Genzyme Corporation ] - Source: HCMSv3 |
| 5 | , "PHASE 2 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALELL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF A PHOSPHODIESTER 5 IF -0048979 IN ADULTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY" (14.12.2011 - 14.03.2012) [ Pfizer (M) Sdn Bhd ] - Source: HCMSv3 |
| 6 | , "A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED, 3 ARM PARALLEL GROUP 18 WEEK MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF CANAGLIFOZIN COMPARED WITH PLACEBO IN THE TREATMENT OF SUBJECTS WITH TYPE 2 DIABETES MELLITUS WITH INAD" (01.06.2011 - 04.12.2013) [ JANSSEN-CILAG (Johnson & Johnson Pharmaceutical Research & Development ) ] - Source: HCMSv3 |
| 7 | , "MK3102-006: A PHASE IIB,RANDOMIZED,PLACEBO-CONTROLLED DOSE-RANGE FINDING CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF MK 3102 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL" (02.11.2010 - 09.10.2014) [ Merck, Sharp & Dohme (MSD) ] - Source: HCMSv3 |
| 8 | , "A RANDOMISED, DOUBLE BLIND, PLACEBO AND ACTIVE CONTROLLED, 4-ARM, PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF CANAGLIFTOZIN COMPARED WITH SITAGLIPTIN AND PLACEBO IN THE TREATMENT OF SUBJECTS WITH TYPE 2 DIAB" (01.01.2010 - 31.12.2010) [ Johnson & Johnson Pharmaceutical Research & Development ] - Source: HCMSv3 |
| 9 | , "A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF CANAGLIFTOZIN AS MONOTHERAPY IN THE TREATMENT OF SUBJECTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED WIT" (01.01.2010 - 31.12.2010) [ Johnson & Johnson Pharmaceutical Research & Development ] - Source: HCMSv3 |
| 10 | , "A RANDOMIZED MULTICENTER, DOUBLE-BLIND,PARALLEL PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF CANAGLIFOZIN (JNJ-28431754) ON CARDIOVASCULAR OUTCOMES IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS (CANVAS TRIAL)" (03.12.2009 - 08.12.2016) [ Johnson & Johnson Sdn.Bhd ] - Source: HCMSv3 |
| 11 | , "A PHASE III RANDOMIZED, ACTIVE-COMPARATOR (PIOGLITAZONE) CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF MK 0431A ( A FIXED DOSE COMBINATION TABLET OF SITAGLIPTIN AND METFORMIN) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS" (30.11.2007 - 18.11.2009) [ Merck & Co. INC ] - Source: HCMSv3 |
| 12 | , "PHASE IIB/III, PLACEBO CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF MK 0364 IN OVERWEIGHT AND OBESE PTS IN T2DM" (01.10.2007 - 27.09.2010) [ Novonordisk ] - Source: HCMSv3 |
| 13 | , "MULTICENTER, DOUBLE BLIND , RANDOMISED, PLACEBO AND ACTIVE COMPARATOR CONTROLLED DOSE RANGE FINDING STUDY OF MK-0893 IN T2DM" (01.09.2007 - 01.10.2010) [ Novonordisk ] - Source: HCMSv3 |
| 14 | , "MK-0893: A MULTICENTRE DOUBLE BLIND RANDOMIZED PLACEBO AND ACTIVE COMPARATOR CONTROL DOSE RANGE FINDING STUDY OF MK-0893 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE IN ADEQUATE GLYCAEMIC CONTROL" (01.07.2007 - 31.01.2008) (01) [ Merck Sharp and Dohme (I.A.) Corp ] - Source: HCMSv3 |
| 15 | , "MK-0431-052: A PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF THE ADDITION OF SITAGLIPTIN (MK-041) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL ON COMBINATION THERAPY WITH" (02.07.2006 - 01.06.2008) (01) [ Merck Sharp & Dohme (I.A) Corp.USA ] - Source: HCMSv3 |
| 16 | , "MK-0533-005: AN EFFICACY AND TOLERABILITY STUDY OF MK-0533 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL" (04.06.2006 - 03.09.2006) (01) [ Merck Sharp & Dohme (I.A) Corp.USA ] - Source: HCMSv3 |
| 17 | , "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, “FACTORIAL� DESIGN STUDY TO EVALUATE THE LIPID-ALTERING EFFICACY AND SAFETY OF MK-0524B IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED HYPERLIPIDAEMIA." (01.01.2006 - 01.06.2006) (01) [ Merck Sharp & Dohme (I.A) Corp.,USA ] - Source: HCMSv3 |